News | May 02, 2026
Bayer pushes stroke prevention drug forward in China as regulators accept key filing
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
The approval now covers procedures using 10-14F inner diameter and up to 17F outer diameter procedural sheaths
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
Complementary business models are the reason for the acquisition
Subscribe To Our Newsletter & Stay Updated
